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Abstract
Loss of hSNF5 function is usually observed in malignant rhabdoid tumor (MRT), a highly aggressive
pediatric neoplasm. Previous studies have shown that reexpression of hSNF5 in MRT cell lines causes
G1 cell cycle arrest with p16INK4A, p21CIP1/WAF1 and cyclin D1 playing key roles in MRT cell growth
control. However, we have shown that reexpression of hSNF5 induced cell cycle arrest in the absence
of p16INK4A expression. These results indicate that the mechanism of hSNF5-induced cell cycle
arrest is context dependent. Here, we investigated the relationship between p21CIP1/WAF1 and hSNF5
in the regulation of growth using several MRT cell lines. We found that G1 cell cycle arrest occurred
concomitant with an increase in p21CIP1/WAF1 mRNA and protein levels and preceeded p16INK4A
mRNA and protein up-regulation. Chromatin immunoprecipitation data confirmed that hSNF5
appeared at both p21CIP1/WAF1 and p16INK4A promoters after reexpression. We further showed that
p21CIP1/WAF1 induction showed both p53 dependent and independent mechanisms. We also
demonstrated that reduction of p21CIP1/WAF1 expression by RNAi significantly inhibited hSNF5-
induced G1 arrest. Our results demonstrate that both p21CIP1/WAF1 and p16INK4A are targets for
hSNF5, and that p21CIP1/WAF1 up-regulation during hSNF5-induced G1 arrest precedes p16INK4A
up-regulation. These findings indicate that SNF5 mediates a temporally controlled program of CDK
inhibition to restrict aberrant proliferation in MRT cells.
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Introduction
Malignant rhabdoid tumor (MRT) is a rare and extremely aggressive childhood cancer. MRT
was initially described as an unfavorable histologic type of pediatric renal tumor, a variant of
Wilms’ tumor (1). While the most common locations occur in the kidney and central nervous
system, MRT also arise in almost any site (2,3). Despite significant advances in the treatment
and outcome of other pediatric tumors, for MRTs diagnosed before the age of 6 months, patient
survival at 4 years drops to approximately 8.8% (4). Therefore, improved patient outcome
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requires a better understanding of malignant rhabdoid tumorigenesis and the development of
novel therapeutic strategies.
In the past several years, the discovery of deletions and mutations at 22q11.2 involving hSNF5/
INI1 has contributed to the clarification of pathogenesis of MRT (5). The finding that genetic
alterations in MRTs are usually limited to hSNF5 mutations and deletions implicates the loss
of hSNF5 function as the primary cause of these tumors. Now, hSNF5 function is recognized
as being lost in almost 100% of MRTs (6,7). Therefore, the elucidation of hSNF5 function
should lead to the identification of the key molecular steps necessary for MRT tumorgenesis.
hSNF5 is one of the core subunits of the SWI/SNF chromatin remodeling complex that also
includes an ATPase subunit (either BRG1 or BRM), BAF155, and BAF170. SWI/SNF
complexes are ATP-dependent chromatin remodeling complexes that regulate gene
transcription by causing conformational changes in chromatin structure, as well as by
cooperation with histone acetylation complexes (8). In human cells, studies have shown a role
for transcriptional regulation by SWI/SNF complexes in the control of cell growth, tissue
differentiation, and embryo development in multiple tissues (9). Furthermore, loss of BRG1
function has been observed in malignant tumors including lung, pancreatic, breast, and prostate
cancer (10-13). Several new SWI/SNF members, such as BAF180, have been found to form
different subsets of SWI/SNF complexes with distinct functions (14-16). To understand how
the SWI/SNF complex regulates gene expression in a complex and precise manner has become
increasingly important.
Recently, several reports have shown that hSNF5 plays key roles in cell cycle control,
differentiation, and oncogenic transformation. Reexpression of hSNF5 induces G1 cell cycle
arrest in MRT cell lines, accompanied by up-regulation of p16INK4A and down-regulation of
cyclin D1, cyclin A, and phosphorylated retinoblastoma protein (pRb), suggesting a key role
for these genes in MRT cell cycle control (17-20). Kia et al. reported reexpression of hSNF5
mediates eviction of polycomb complex proteins such as BMI-1 from epigenetically silenced
promoters of the INK4b-ARF-INK4a locus followed by their activation (21). Furthermore,
some reports demonstrated that hSNF5 controls the differentiation of MRT cells (22,23) and
hSNF5 loss changes gene transcription epigenetically and contributes to oncogenesis without
genomic instability (24).
Our previous study showed that reexpression of hSNF5 induced cell cycle arrest even in the
absence of p16 INK4A expression (25). This finding suggested that other genes besides
p16INK4A play a critical role at early time points of G1 cell cycle arrest induced by hSNF5.
Therefore, in this study, we determined the mechanism of G1 cell cycle arrest induced by
hSNF5 in MRT cells within 24 hours after reexpression using adenoviral vectors. We show
that induction of p21WAF1/CIP1 appears at the onset of hSNF5-induced growth arrest and
precedes p16INK4A expression. Furthermore, we demonstrate that p21WAF1/CIP1 knock-down
inhibits hSNF5-induced G1 cell cycle arrest. We also show differences in the histone
methylation changes at these 2 promoters after hSNF5 reexpression. Finally, we demonstrate
that p21WAF1/CIP1 shows both p53 dependent and independent mechanisms of induction after
hSNF5 reexpression. Our results suggest that p21WAF1/CIP1 plays a key role in hSNF5 control
of cell growth, and hSNF5 loss may alter p21WAF1/CIP1 transcription by a different mechanism
than that reported for the p16 INK4A promoter in MRT cells.
Materials and Methods
Cell culture and adenovirus infection
A204.1 (ATCC), G401.6 (ATCC), TTC642 (Dr. Timothy Triche- Childrens Hospital of Los
Angeles), and NIH3T3 (Dr. Stuart Aaronson-National Cancer Institute) cells were cultured in
Kuwahara et al. Page 2













RPMI 1640 medium and UNC N3T cells in bronchial epithelial growth medium (BEGM)
(26). 293FT cells were cultured in DMEM medium containing 10% fetal bovine serum. The
Ad/pAdEasyGFPINI-SV+ adenoviral vectors expressing hSNF5 and co-expressing the green
fluorescent protein (GFP) (designated Ad-hSNF5) and the Ad/pAdEasyGFP expressing GFP
(designated Ad-GFP) were previously published (20). In order to achieve infection of over
90% cells, we infected at a multiplicity of infection (M.O.I.) of 20 for the A204.1 cell line and
200 for the TTC642 cell line.
Protein extracts and Western blotting
Western blotting was carried out as described previously (25). Western analyses of proteins
were carried out by using anti-p21CIP1/WAF1 (AB1; Calbiochem), anti-p16INK4a (G175-1239;
BD Pharmingen), anti-pRb (G3-245; BD Pharmingen), anti-actin (A2066; Sigma), anti-p53
(DO-1; Santa Cruz), anti–cyclin A (H-432; Santa Cruz Biotechnology), anti-hSNF5 (BD
Transduction Laboratories), BMI-1 (upstate cloneF6; Millipore), and horseradish peroxidase–
conjugated anti-rabbit or anti-mouse IgG (GE Healthcare).
RNA extraction and Quantitative real-time reverse transcription-PCR analysis
RNA was extracted using the RNeasy mini kit (Qiagen), and 1 μg was used for cDNA synthesis
primed with Random Primers (Invitrogen). cDNA was analyzed using TaqMan (Applied
Biosystems) quantitative real-time reverse transcription-PCR (QT-PCR) analysis with β-
actin as the reference gene in each reaction. Reactions were performed on an ABI 7900 HT
sequence detection system (Applied Biosystems) and relative quantification was determined
using the 2−ΔΔCt method (27). The primers used for p16INK4a QT-PCR were 5′-
CTGCCCAACGCACCGAATA-3′ and 5′-GCGCTGCCCATCATCATGA-3′. The probe
used for p16INK4a QT-PCR was 5′-CTGGATCGGCCTCCGACCGTA-3′. The TaqMan gene
expression assay primer/probe set (Hs00355782_m1; Applied Biosystems) was used for
p21CIP1/WAF1, the primer/probe set (Hs01034249_m1; Applied Biosystems) was used for p53,
and the primer/probe set (Hs99999903_m1; Applied Biosystems) was used for β-actin.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIPs) was carried out as described by Donner et al (28).
Immunoprecipitation was performed with an antibody specific to hSNF (Dr. Tony Imbalzano),
histone H3 trimethylation of lysine 4 (H3K4 me3) (ab8580; Abcam), BRG-1 (J1; Dr. Weidong
Wang), BMI-1 (upstate cloneF6; Millipore), normal Rabbit IgG (sc-2027; Santa Cruz
Biotechnology), normal mouse IgG (sc-2025; Santa Cruz Biotechnology) or p53 (DO-1;
Calbiochem). DNA present in each IP was quantified by QT-PCR using gene-specific primers
on an ABI 7000 sequence detection system. All expression values were normalized against
input DNA. Antibody specificity was also determined for each cell line (Supplementary Figure
1). The primer sequences are shown in Supplementary Table 1.
Lentiviral procedures and shRNA
Lentivirus was generated using 293FT cells following the protocol of Kafri and co workers
(29). Either pLKO.1, a non-target shRNA control vector (SHC002; Sigma), an equal mixture
of 5 types of NM_00039 p21 MISSION shRNA Lentiviral Transduction Particles
(TRCN0000040123, TRCN0000040124, TRCN0000040125, TRCN0000040126 and
TRCN0000040127) or NM_000546 p53 MISSION shRNA Lentiviral Transduction Particles
(TRCN0000003756), obtained from Sigma, were co-transfected with the packing construct
ΔNRF (from Dr. Tal Kafri, The University of North Carolina) (29), and the VSV-G envelope
expression plasmid (pMDK64; from Dr. Matthias Kaeser, The Salk Institute) into 293FT cells
with FuGene® (Roche). pLKO.1 is a negative control containing an insert sequence that does
not target any human or mouse gene, but will activate the RNAi pathway. For infection, cells
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were incubated with lentiviral particles and polybrene and then selected with puromycin. At
least 3 puromycin-resistant colonies of the A204.1 and TTC642 cells were isolated and
expanded for further characterization.
Cell cycle analysis
Cell cycle analyses were performed according to the procedure of Huang S et al. (30).
Percentages of cells within each of the cell cycle compartments were determined by flow
cytometry (CyAn; Dako) and analyzed with ModFit software (Verity).
Results
The effects of reexpression of hSNF5 on the growth of MRT cell lines
We have previously shown that both hSNF5 and p16INK4A can induce G1 cell cycle arrest in
MRT cell lines at 72 hours after transfection (19). However, hSNF5 also induced G1 cell cycle
arrest without p16INK4A induction in the same timeframe (25). Because of the extended period
between hSNF5 transfection and the characterization of cell cycle arrest in these previous
studies, we characterized the effects of hSNF5 expression on the growth of 2 MRT cell lines
within 24 of infection with Ad-hSNF5 and Ad-GFP (negative control) adenoviruses.
The induction of hSNF5 protein expression in the A204.1 and TTC642 cells by adenoviral
infection is shown in Figure 1A. No hSNF5 expression was detected in either MRT cell line
in the absence of infection or after Ad-GFP infection. However, infection with Ad-hSNF5 led
to hSNF5 expression as early as 12 hours post-infection, followed by a time-dependent increase
in hSNF5 expression levels in both MRT cells lines.
We next tested the effects of hSNF5 reexpression on cell cycle regulation by flow cytometry.
Both cell lines infected with Ad-hSNF5 showed cell cycle arrest 24 hours after infection,
characterized by the presence of nearly 80% of cells in the G1 phase of the cell cycle and the
presence of <10% of cells in the S phase (Fig. 1B). The percentage of Ad-hSNF5- and Ad-
GFP-infected cells in S phase was significantly different at 24 hours after infection. Similar
results were found at 48 hours post-infection. These results demonstrated that the G1-S cell
cycle progression was inhibited by 24 hours after hSNF5 reexpression in these MRT cell lines.
hSNF5-induced p16INK4A and p21CIP1/WAF1 protein expression in MRT cell lines
We previously demonstrated that hSNF5 reexpression induced the down-regulation of Cyclin
A, the dephosphorylation of pRb, and up-regulation of p16INK4A and p21CIP1/WAF1 expression
at 3 days following transfection (25). To determine whether these changes also occurred
simultaneously with hSNF5-induced cell cycle arrest at 24 hours post-infection, we examined
the expression of cyclin dependent kinase (CDK) inhibitors, especially p16INK4A and
p21CIP1/WAF1, as well as their downstream targets by western blotting (Fig. 1C). We observed
increased p21CIP1/WAF1 and decreased phosphorylated-pRb and cyclin A levels at 24 hours
after Ad-hSNF5 infection compared to Ad-GFP control and un-infected control in both A204.1
and TTC642 cells. In the A204.1, p16INK4A protein levels were increased slightly at 12 hours
after Ad-hSNF5 infection, and showed a further increase at 24 hours after infection compared
to control cells. In contrast, p16INK4A protein expression was absent at baseline in the TTC642,
with a slight increase at 24 hours, followed by a marked increase at 48 hours after infection.
On the other hand, p53 was not significantly changed in both MRT cell lines (Fig. 1C).
Reexpression of hSNF5 induces p21CIP1/WAF1 transcription with or without p53 recruitment
in MRT cell lines
We next examined whether the increase in p21CIP1/WAF1 protein levels resulted from an
increase in its mRNA levels by QT-PCR. We found the level of p21CIP1/WAF1 mRNA increased
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within 12 hours after Ad-hSNF5 infection in comparison with Ad-GFP infection in both MRT
cell lines. In the TTC642, p21CIP1/WAF1 also increased more with Ad-GFP infection than un-
infected control, especially at 48 hours (Fig. 2A).
In our previous study, we showed hSNF5 regulated p21CIP1/WAF1 and p16INK4A transcription
in A204.1 at 4 days after hSNF5 plasmid transfection by ChIPs (25). Therefore, we analyzed
the chromatin status at p21CIP1/WAF1 promoter, −2283 kb (p53 high-affinity binding site) and
−1391 kb (p53 low-affinity binding site) in both A204.1 and TTC642 cells (28), at 24 hours
after Ad-hSNF5 infection to clarify the mechanism of p21CIP1/WAF1 activation by hSNF5.
ChIPs data confirmed that hSNF5 bound to both −2283 kb site and −1391 kb site in either cell
line. Furthermore BRG1 is also recruited by hSNF5 induction to both sites in A204.1, but only
at the −2283 site in TTC642 (Fig. 2B).
Moreover, our previous reports also suggested hSNF5 recruits p53 to the p21 promoter (25).
Therefore, we determined whether hSNF5 recruitment to the p21 promoter affected p53
binding. In A204.1, p53 binding is increased after hSNF5 reexpression, with a higher amount
detected at the high affinity −2283 kb site (Fig. 2B). In contrast, we did not observe a difference
in p53 recruitment between Ad-hSNF5 infection and Ad-GFP infection in the TTC642
although the difference in binding between the 2 affinity sites remained (Fig. 2B). We next
determined the effect of hSNF5 reexpression on the H3K4me3, a chromatin mark associated
with gene activation (31). H3K4me3 decreased after hSNF5 reexpression at both the −2283
kb and −1391 kb sites in both the A204.1 and TTC642 cells (Fig. 2B).
Reexpression of hSNF5 induces p21CIP1/WAF1 transcription through both p53-dependent and
p53-independent mechanisms in MRT cell lines
Because our results indicated that hSNF5 reexpression activated p21CIP1/WAF1 transcription
with p53 recruitment in A204.1 cells but without p53 recruitment in TTC642 cells, we next
assessed the role of p53 in p21CIP1/WAF1 transcription in the MRT cell lines. We established
2 independently derived p53 stable knock-down MRT cell lines from both A204.1 and TTC642
cells using lentiviral vectors encoding a small hairpin RNA (shRNA) targeting p53 mRNAs.
We also developed a negative control cell line using a lentiviral vector encoding a small hairpin
RNA targeting a non-mammalian sequence (pLKO.1). By QT-PCR and Western blotting, all
p53 knock-down cells (A204.1 p21KD and TTC642 p21 KD) showed significant decreases in
the p53 mRNA levels along with the protein levels of p53 and p21CIP1/WAF1 compared with
the parental cells or the control cells (A204.1 pLKO.1 and TTC642 pLKO.1) (Fig. 3A).
We next determined whether the reduction in p53 expression affected p21CIP1/WAF1
transcription induced by hSNF5. Infection of the pLKO.1 and p53KD cells with Ad-hSNF5
or Ad-GFP resulted in increased levels of p21CIP1/WAF1 mRNA at 24 hours after Ad-hSNF5
infection in pLKO.1 cells as in the parental cell lines (Fig.3B). However, while the increase of
p21CIP1/WAF1 mRNA by hSNF5 reexpression was significantly inhibited in all A204.1 p53KD
cells, the increase of p21CIP1/WAF1 mRNA by hSNF5 reexpression was not significantly
different among TTC642, TTC642 pLKO.1 and all TTC642 p53KD cells (Fig. 3B). These
results suggested that the up-regulation p21CIP1/WAF1 transcription by hSNF5 reexpression
was operated through p53-dependent mechanism in A204.1 cells and through a p53-
independent mechanism in TTC642 cells.
Reexpression of hSNF5 induces p16INK4A transcription through BMI-1 eviction in the TTC642
cell line
Although the A204.1 expresses p16INK4A mRNA and protein, the TTC642 does not show
detectable expression of p16INK4A protein. However, reexpression of hSNF5 caused up-
regulation of p16INK4A protein in both MRT cell lines (Fig. 1C). We, therefore, examined
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whether the increase of p16INK4A protein resulted from an increase in its mRNA levels by QT-
PCR. We found that p16INK4A mRNA levels increased within 24 hours and 48 hours after Ad-
hSNF5 infection in the A204.1 and in TTC642 cells, respectively (Fig. 4A). These results
demonstrated the increase in p21CIP1/WAF1 mRNA occurs earlier than the increase in
p16INK4A mRNA.
Because BMI-1 represses transcription at p16INK4A locus (32) and an earlier report indicated
that p16INK4A transcription is activated by induction of hSNF5 via BMI-1 eviction (21), we
first confirmed that hSNF5 binding at the p16INK4A promoter increased at 24 hours after Ad-
hSNF5 infection in both cell lines (Fig. 4B). We next determined the binding of BMI-1 to the
p16INK4A promoter as an indication of polycomb complex silencing. In TTC642, we observed
BMI-1 binding was also significantly less after infection of Ad-hSNF 24 and 48 hours after
infection compared with control infected cells (Fig. 4B). We also found a modest increase in
BRG-1 binding on the p16INK4A promoter after hSNF5 reexpression at 24 hours followed by
a dramatic increase in H3K4 me3 binding at 48 hours in TTC642 cells (Fig. 3B, 3C). These
results appear consistent with hSNF5 reexpression increasing the binding of the SWI/SNF
complex to the p16INK4A promoter accompanied by polycomb eviction at 24 hours followed
by H3K4 methylation, and activation of p16INK4A transcription at 48 hours in TTC642 cells.
In contrast, we detected little BMI-1 binding on the p16INK4A promoter in A204.1 cells, even
in the absence of hSNF5 expression (Fig. 4B). We also observed that hSNF5 reexpression had
little effect on the binding of BRG-1 and the level of H3K4 methyation at this promoter (Fig.
4B, C). These results suggested an absence of polycomb complex silencing at the p16INK4A
promoter in the A204.1 cells. Therefore, we examined the expression of BMI-1 in our MRT
cell lines by Western blotting. The results in Figure 4F demonstrate that the A204.1 cell line
fails to express detectable BMI-1 protein compared to the TTC642 cell line (Fig. 4D). The
absence of BMI-1 may explain the basal level of p16INK4A mRNA observed in A204.1 cells.
Reduced p21CIP1/WAF1 expression inhibits the G1 arrest induced by re-expression of hSNF5
in MRT cell lines
Because our results indicated that hSNF5 reexpression activated p21CIP1/WAF1 transcription
earlier than p16INK4A transcription, we next assessed the role of p21CIP1/WAF1 in hSNF5-
induced cell cycle arrest in the MRT cell lines. We established 3 independently derived
p21CIP1/WAF1 stable knock-down MRT cell lines from both A204.1 and TTC642 cells using
lentiviral vectors encoding a small hairpin RNA (shRNA) targeting p21CIP1/WAF1 mRNAs and
a negative control cell line (pLKO.1). By QT-PCR and Western blotting, all p21CIP1/WAF1
knock-down cells (A204.1 p21KD and TTC642 p21 KD) showed significant decreases in the
mRNA levels along with the protein levels of p21CIP1/WAF1 compared with the parental cells
or the control cells (A204.1 pLKO.1 and TTC642 pLKO.1) (Fig. 5A).
We next determined whether the reduction in p21CIP1/WAF1 expression affected hSNF5
induced cell cycle arrest. Therefore, we infected the pLKO.1 and p21KD cells with Ad-hSNF5
or Ad-GFP, and assayed the effects on cell cycle by flow cytometry. We observed a similar
G1 cell cycle arrest induced by Ad-hSNF5 infection in pLKO.1 cells after 24 hours as in the
parental cell lines (Fig. 5B). However, the inhibition of the G1-S cell cycle progression by
hSNF5 reexpression was significantly inhibited in all A204.1 p21KD cells and TTC642 p21KD
cells (Fig. 5B). These results indicated that p21CIP1/WAF1 up-regulation contributes to the
inhibition of the G1-S cell cycle progression by hSNF5 at 24 hours after Ad-hSNF5 infection.
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Reduced p21CIP1/WAF1 expression inhibits the dephosphorylation of pRb after hSNF5
reexpression in MRT cell lines
Because p21CIP1/WAF1 knock-down caused inhibition of G1 cell cycle arrest induced by hSNF5
reexpression, we examined whether the effect occurred at the level of pRb phosphorylation.
Although p21CIP1/WAF1 expression increased after hSNF5 reexpression in A204.1 pLKO.1
and TTC642 pLKO.1 cell lines, we observed limited increase of p21CIP1/WAF1 and limited
reduction of phosphorylated-pRb and cyclin A at 24 hours after Ad-hSNF5 infection in A204
p21KD cells and TTC642 p21KD cells (Fig. 6A & B). The expression of p16INK4A was not
significantly increased at 24 hours after Ad-hSNF5 infection in A204.1 p21KD cells. In
TTC642 p21KD cells, the p16INK4A protein increased slightly at 24 hours after Ad-hSNF5
infection (data not shown), then increased significantly at 48 hours, similar to the TTC642
parent cell line (data not shown). The change of p21CIP1/WAF1 mRNA was similar to the results
seen with p21CIP1/WAF1 protein levels (data not shown). Taken together, these results indicated
that the G1 arrest induced by hSNF5 reexpression strongly correlated with dephosphorylation
of pRb through p21 CIP1/WAF1 activation.
Discussion
By studying the mechanism of G1 cell cycle arrest induced by hSNF5 at a time point
concomitant with the induction of growth arrest, our study shows three important observations.
First, hSNF5 directly regulates the p21CIP1/WAF1 and p16INK4A loci through different
mechanisms among MRT cell lines. Second, hSNF5 can regulates the p21CIP1/WAF1 through
either a p53-dependent or a p53-independent mechanism. Finally, p21CIP1/WAF1 has a key role
in hSNF5-induced cell growth arrest in MRT cell lines.
Reexpression of hSNF5 increased p21CIP1/WAF1 transcriptional activity immediately through
the recruitment of BRG1 to the p21CIP1/WAF1 promoter. Similarly, some reports have suggested
that BRG1 associates with the p21CIP1/WAF1 promoter and activates it along with hSNF5
(33,34). Does this recruitment of the SWI/SNF complex lead to an interaction with another
transcription factor? Lee et al. (35) suggested that the BRG-1 interacts with p53 and activates
the p21CIP1/WAF1 promoter in a p53-dependent manner. In contrast, Liu et al. (36) and
Hendricks et al. (33) suggested that BRG-1 activates the p21CIP1/WAF1 promoter in p53-
independent manner. Indeed, previous reports have shown that multiple mechanisms can
activate the p21CIP1/WAF1 promoter including p53-dependent, Sp1- or Sp3-dependent, or
CDK8-dependent (37). Our results in the A204.1 cell line appear consistent with the former
model. We observed increased p53 levels at the p21CIP1/WAF1 promoter after hSNF5
reexpression and reduction in p53 expression inhibited up-regulation of p21CIP1/WAF1 induced
by hSNF5. This finding, at a minimum, supports the notion that reexpression of hSNF5 in these
cells facilitates the recruitment of p53 to the p21CIP1/WAF1 promoter. However, our studies did
not determine whether this occurs through a direct interaction between p53 and hSNF5. We
also need to identify the upstream signal that initiates p53 binding to the p21CIP1/WAF1
promoter.
In contrast, p53 levels on p21CIP1/WAF1 did not change in the TTC642 cells after hSNF5
reexpression nor did decreased p53 levels affect the ability of hSNF5 to increase
p21CIP1/WAF1 transcription. While we cannot exclude the possibility that a low level of p53
protein remains at the p21CIP1/WAF1 promoter, sufficient for transcriptional activation, it
appears that hSNF5 reexpression may operate through a different mechanism in these cells.
While activation of p21CIP1/WAF1 transcription by hSNF5 in both cell lines appears associated
with recruitment of BRG-1, the transcription factors recruited to the p21CIP1/WAF1 promoter
may differ. Additional ChIPs analyses of the p21CIP1/WAF1 promoter in the TTC642 cell line
will clarify this matter. In addition, our result showed a modest increase in p21CIP1/WAF1
transcription after Ad-GFP infection compared to the uninfected control. We believe that the
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high M.O.I. of adenovirus required for infection of this cell line caused up-regulation of
p21CIP1/WAF1 through apoptotic induction (38).
We also showed that reexpression of hSNF5 increases p16INK4A transcriptional activity after
p21CIP1/WAF1 up-regulation. In TTC642 cell line, hSNF5 expression caused decrease of BMI-1
and increase of BRG-1 at the p16INK4A promoter. The level of BMI-1 at 48 hours was less
than that at 24 hours, and the decrease of BMI-1 was correlated with an increase of H3K4me3.
These results concur with the Kia et. al. report showing hSNF5 induced a decrease of BMI-1
and an increase of H3K4me3 on the p16INK4A promoter, and that BRG1 was necessary for
activation of the p16INK4A promoter by hSNF5 (21). On the other hand, the A204.1 cell line
expresses low basal levels of p16INK4A consistent with a lack of expression of BMI-1. Our
results appear in accord with the report that p16INK4A expression is directly regulated by
polycomb proteins such as BMI-1 and EZH2 (39). Moreover, while hSNF5 appeared at
p16INK4A promoter after reexpression followed by an increase in p16INK4A mRNA in the
A204.1 cell line, BRG-1 and H3K4me3 levels at the promoter did not change significantly.
Therefore, in the absence of polycomb silencing, p16INK4A mRNA could increase more rapidly
in the A204.1 cell line than in the TTC642 cell line. Regardless, the data still show that the
hSNF5-induced increase in p16INK4A levels in the A204.1 cell line follows the
p21CIP1/WAF1 up-regulation regardless of BMI-1 expression. The mechanism for the increase
in p16INK4A mRNA in the A204.1 cell line requires further investigation.
The difference in H3K4me3 patterns between the p21CIP1/WAF1 and p16INK4A promoters was
unexpected. The significant increase in H3K4me3 at the p16INK4A promoter (−450 kb) in the
TTC642 cell line after hSNF5 reexpression appears consistent with the activation of
transcription from this promoter. Although the levels of this modification did not change in
the A204.1 cell line, this may reflect the active p16INK4A transcription present in these cells
before hSNF5 reexpression. However, in both cell lines, H3K4me3 decreased at the p53
binding sites in the p21CIP1/WAF1 promoter (−2283 kb and −1391 kb) after hSNF5
reexpression, even though p21CIP1/WAF1 transcription increased. One possible explanation for
this observation might come from hSNF5 reexpression activating SWI/SNF complex activity
resulting in nucleosome repositioning by chromatin remodeling. Therefore, the subsequent
change in H3K4me3 positioning on the p21CIP1/WAF1 promoter would be reflected by a
decreased signal in our ChIPs assay.
In our study, p21CIP1/WAF1 knock-down experiments showed that inhibition of
p21CIP1/WAF1 expression partially inhibited the efficiency of hSNF5-induced G1 cell cycle
arrest in MRT cell lines. The failure to completely abrogate the growth arrest may result from
the residual activation of p21CIP1/WAF1 protein in the RNAi-expressing MRT cell lines. In
addition, the increasing levels of p16INK4A protein may also begin to affect the cells because
we observed a complete cell cycle arrest at 48 hours in the p21 knock-down cells (unpublished
observations). We also cannot exclude the possibility that altered expression of other cell cycle
regulatory genes may contribute the G1 arrest induced by hSNF5 (40,41). This result indicated
that p21CIP1/WAF1 has a key role in hSNF5-induced cell growth arrest in MRT cell lines.
Importantly, Smith et al. recently showed cell cycle arrest and cytotoxicity induced by
flavopiridol in MRT cell lines correlated with the down-regulation of cyclin D1 and the up-
regulation of p21CIP1/WAF1 (42). Taken together, these results support p21CIP1/WAF1 as a
relevant target for therapy of MRT.
Many MRTs arise under in infants under the age of 6 months and in neonates (43). Therefore,
it seems plausible that a significant number of MRTs arise from the loss of hSNF5 in stem
cells or progenitor cells during development. The expression of p16INK4A in stem cells is
restricted by the expression of BMI-1 (44). Indeed, mouse embryo cells do not display
expression of p16INK4A (45) and stem cells in young mice (8-12 week old) do not express
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detectable p16INK4A mRNA (46). Thus, a strong possibility exists that p16INK4A was already
silenced in the cell that gave rise to the TTC642 cell line before hSNF5 loss occurred.
Our results may indicate that a decrease in p21CIP1/WAF1 expression following hSNF5 loss
may signify one key event during MRT development. For example, the absence of
p21CIP1/WAF1 expression can increase hematopoietic stem cell proliferation (47) or maintain
neural stem cells by playing a significant role in regulating their proliferation (48). Our recent
studies showing cooperation between SNF5 loss and pRb family inactivation in the acceleration
of formation of spinal cord MRTs in mice support this notion (49). These results suggest that
p21CIP1/WAF1 and its down-stream targets may regulate the boundary between quiescence and
proliferation in stem cells and progenitor cells.
In conclusion, our results demonstrated that while hSNF5 reexpression in MRT cells increases
both p21CIP1/WAF1 and p16INK4A expression during the induction of G1 cell cycle arrest,
p21CIP1/WAF1 up-regulation precedes p16INK4A. While our studies firmly substantiate
p21CIP1/WAF1 as a key target for hSNF in cell cycle regulation, the role of hSNF5 within the
activities of SWI/SNF complex and gene regulation appear complex. Studies from other
laboratories also implicate a role for hSNF5 the regulation cellular differentiation, cell
migration and DNA repair (40,41,50). However, the establishment that SNF5 loss alters
p21CIP1/WAF1 expression during MRT tumorigenesis provides an important new target for
therapy in a tumor with limited options for treatment.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. G1 cell cycle arrest induced by reexpression of hSNF5
(A) Cells were harvested at the indicated times after infection with Ad-hSNF5 and Ad-GFP.
Total cell protein (30 μg) were separated on a 4-20% SDS-polyacrylamide gel and probed with
either anti-SNF5 or anti-ß-actin. un; uninfected control. (B) Twenty-four hours after infection
with Ad-hSNF5 or Ad-GFP, cells were harvested and analyzed by flow cytometry. Left,
representative profiles; Right, Values are the mean of three independent experiments; bars, ±
SD. *, P < 0.05 relative to the number of S-phase of un-infection control. (C) Cells were
harvested at the indicated times after infection with Ad-hSNF5 and Ad-GFP. Total cell protein
(30 μg) were separated on a 4-20% SDS-polyacrylamide gel and probed with appropriate
antibodies. un; uninfected control.
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Figure 2. hSNF5-induced p21CIP1/WAF1 expression
(A) RNA was extracted at the indicated times after infection with Ad-hSNF5 and Ad-GFP.
The mRNA levels were measured for each gene by QT-PCR and normalized for β-actin
expression. Values are the mean of three independent experiments; bars, ± SD. *, P < 0.05
relative to the Ad-GFP and un-infected control. un; uninfected control. (B) At 24 hours after
infection with Ad-hSNF5 and Ad-GFP, protein was extracted for ChIPs assays. ChIPs assays
were performed using antibodies directed against hSNF5, BRG-1, p53 and H3K4me3 on −2283
kb and −1391 kb of p21CIP1/WAF1 promoter. Values are the mean of triplicates; bars, ± SD. *,
P < 0.05 relative to the Ad-GFP control. **, P < 0.01 relative to the Ad-GFP control. #, P >
0.05 relative to the Ad-GFP control.
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Figure 3. p21CIP1/WAF1 expression after reexpression of hSNF5 in p53 stable knock down MRT
cells
(A) p53 knock-down cells (A204 p53KD and TTC642 p53 KD) and the control cells (A204
pLKO.1 and TTC642 pLKO.1) were harvested and RNA and protein was extracted. The
mRNA levels were measured by QT-PCR for each gene and normalized for β-actin expression.
Values are the mean of three independent experiments; bars, ± SD. Total protein (30 μg) was
separated on a 4-20% SDS-polyacrylamide gel and probed with appropriate antibodies. (B)
Every 24 hours after infection with Ad-hSNF5 and Ad-GFP, cells were harvested and RNA
was extracted. The mRNA levels were measured for each gene by QT-PCR and normalized
for β-actin expression. Values are the mean of three independent experiments; bars, ± SD. *,
P < 0.05 relative to the Ad-hSNF5 infected parent cells. #, P > 0.05 the Ad-hSNF5 infected
parent cells.
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Figure 4. hSNF5-induced p16INK4A expression
(A) Cells were infected with Ad-hSNF5 and Ad-GFP. RNA was extracted at the indicated
times after infection. The mRNA levels were measured by QT-PCR analysis for each gene and
normalized for β-actin expression. Values are the mean of three independent experiments; bars,
± SD. *, P < 0.05 relative to the Ad-GFP and un-infected control. un; uninfected control. (B,
C) At 24 and 48 hours after infection with Ad-hSNF5 and Ad-GFP, cells were harvested and
protein was extracted for ChIPs assays. ChIPs assays were performed using antibodies directed
against hSNF5(B), BMI-1(B), BRG-1(B) and H3K4me3(C) on −450 kb site of p16INK4A
promoter. Values are the mean of triplicates; bars, ± SD. *, P < 0.05 relative to the Ad-GFP
control. **, P < 0.01 relative to the Ad-GFP control. #, P > 0.05 relative to the Ad-GFP control.
(D) Total protein (30 μg) were separated on a 4-20% SDS-polyacrylamide gel and probed with
BMI-1 antibody.
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Figure 5. Inhibition of G1 cell cycle arrest by reexpression of hSNF5 in p21CIP1/WAF1 stable knock
down MRT cells
(A) p21CIP1/WAF1 knock-down cells (A204 p21KD and TTC642 p21 KD) and the control cells
(A204 pLKO.1 and TTC642 pLKO.1) were harvested and RNA and protein was extracted.
The mRNA levels were measured by QT-PCR for each gene and normalized for β-actin
expression. Values are the mean of three independent experiments; bars, ± SD. Total protein
(30 μg) was separated on a 4-20% SDS-polyacrylamide gel and probed with p21CIP1/WAF1
antibodies. (B) Every 24 hours after infection with Ad-hSNF5 and Ad-GFP, cells were
harvested and analyzed by flow cytometry. Values are the mean of three independent
experiments; bars, ± SD. *, P < 0.05 relative to each Ad-GFP control.
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Figure 6. Inhibition of pRb dephosphorylation after hSNF5 reexpression in p21CIP1/WAF1 knock-
down MRT cell lines
(A, B) p21CIP1/WAF1 knock-down cells (A204 p21KD and TTC642 p21 KD) and the control
cells (A204 pLKO.1 and TTC642 pLKO.1) were harvested and protein was extracted. Total
cell protein (30 μg) were separated on a 4-20% SDS-polyacrylamide gel and probed with
appropriate antibodies.
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